Anocca, headquartered in Södertälje south of Stockholm, uses gene-editing technology in the development of TCR-T cell therapies—a type of cell therapy that harnesses the natural targeting ability of T cells to identify and eliminate cancer cells.
The treatment targets mutated forms of the KRAS gene, which affect approximately 90 percent of patients with pancreatic cancer.
BREAKING